Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence
Language English Country Germany Media print-electronic
Document type Letter, Research Support, Non-U.S. Gov't
PubMed
32744364
PubMed Central
PMC7754117
DOI
10.1002/eji.202048541
Knihovny.cz E-resources
- Keywords
- adverse late effects, childhood, immune recovery, immunosenescence, neuroblastoma,
- MeSH
- CD8-Positive T-Lymphocytes immunology MeSH
- Immunosenescence immunology MeSH
- Humans MeSH
- Neuroblastoma immunology MeSH
- Cancer Survivors MeSH
- Survivors MeSH
- Risk Factors MeSH
- Tumor Necrosis Factor-alpha immunology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Tumor Necrosis Factor-alpha MeSH
Neuroblastoma survivors show signs of immunosenescence early after therapy in CD8+ T cell compartment and elevated plasma TNF-α but in later follow-up immune recovery comes into play. Whether the recovery phenotype is long lasting or transient remains to be elucidated, however, late adverse effects often occur in childhood cancer survivors.
1st Neurology Department St Anne's University Hospital Brno Brno Czech Republic
Department of Biology Faculty of Medicine Masaryk University Brno Czech Republic
Department of Experimental Medicine University of Perugia Perugia Italy
Department of Paediatric Oncology University Hospital Brno Brno Czech Republic
Department of Pathophysiology 3rd Faculty of Medicine Charles University Prague Czech Republic
Institute of Hematology and Blood Transfusion Prague Czech Republic
International Clinical Research Center St Anne's University Hospital Brno Brno Czech Republic
See more in PubMed
Demaria, M. et al., Cancer Discov. 2017. 7:165–176. PubMed PMC
Phelan, R. et al., Curr. Oncol. Rep. 2019. 21:104. PubMed
Davalos, A R. et al., Cancer Metastasis Rev. 2010. 29:273–283. PubMed PMC
Xu, W. , Larbi, A. , Int. J. Mol. Sci. 201718.
Franceschi, C. et al., Mech. Ageing Dev. 2007. 128: 92–105. PubMed
Freund, A. et al., Trends Mol. Med. 2010. 16:238–246. PubMed PMC
Coppé, J. P. et al., Annu Rev Pathol 2010. 5:99–118. PubMed PMC
Ariffin, H. et al., Cancer 2017. 123:4207–4214. PubMed
Azanan, M. S. et al. Eur. J. Immunol. 2016. 46:1715–1726. PubMed
